$IFF earnings report

IFF Reports Third Quarter 2026 Results Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026 Raising Low-End of Full Year 2026 Financial Guidance Ranges. AlphAI read International Flavors & Fragrances's Third Quarter 2026 filing as solid. 2 quarters are on record below.

Third Quarter 2026

AlphAI · Earnings readIFF · Third Quarter 2026 · ended September 30, 2026

IFF Reports Third Quarter 2026 Results Delivered Strong Sales, Profit and Cash Flow Performance in Third Quarter 2026 Raising Low-End of Full Year 2026 Financial Guidance Ranges

✓Solid quarter

Third-quarter net sales increased 4%, comparable currency neutral sales increased 5%, and adjusted operating EBITDA increased 5% on a reported basis. All three operating segments posted reported sales growth, while the company raised the low ends of its full-year sales, adjusted operating EBITDA, and comparable currency neutral growth ranges. Reported continuing-operations results were affected by a $236 million loss on assets classified as held for sale, resulting in a $(134) million loss before taxes and $(0.50) diluted EPS.

Revenue
$1.94B
4 % y/y
Taste
$687M
4% y/y
EPS · GAAP
$ (0.50)
Full year 2026 outlook
$7.5 billion to $7.6 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Q3 2026 net salesGAAP$1.94B–4 %
Q3 2026 comparable currency neutral salesnon-GAAP$1.95B–5%
Q3 2026 cost of salesGAAP1,117–4 %
Q3 2026 gross profitGAAP825–3 %
Q3 2026 research and development expensesGAAP170–5 %
Q3 2026 selling and administrative expensesGAAP387–11 %
Q3 2026 amortization of acquisition-related intangiblesGAAP78–(7) %
Q3 2026 impairment of goodwillGAAP23–NMF
Q3 2026 restructuring and other chargesGAAP5–(64) %
Q3 2026 operating profitGAAP160–(16) %
Q3 2026 loss from continuing operations before taxesGAAP−$134M–(203) %
Q3 2026 net loss from continuing operationsGAAP−$127M–(228) %
Q3 2026 net lossGAAP$ (55)–(234) %
Q3 2026 net loss attributable to IFF shareholdersGAAP$ (55)–(238) %
Q3 2026 diluted EPS from continuing operationsGAAP$ (0.50)––
Q3 2026 diluted EPSGAAP$ (0.22)––
Q3 2026 adjusted operating EBITDAnon-GAAP$403M–5%
Q3 2026 adjusted operating EBITDA marginnon-GAAP20.8%–0.3%
Q3 2026 comparable currency neutral adjusted operating EBITDAnon-GAAP$404M–6%
Q3 2026 adjusted EPSnon-GAAP$ 0.58––
Q3 2026 adjusted EPS ex. amortizationnon-GAAP$ 0.83––
First nine months 2026 net salesGAAP$5.80B–(1) %
First nine months 2026 gross profitGAAP2,507–1 %
First nine months 2026 operating profitGAAP571–12 %
First nine months 2026 income from continuing operations before taxesGAAP$126M–(81) %
First nine months 2026 net income from continuing operationsGAAP$ 61–(91) %
First nine months 2026 net incomeGAAP$166M–(144) %
First nine months 2026 net income attributable to IFF shareholdersGAAP$164M–(143) %
First nine months 2026 diluted EPS from continuing operationsGAAP$ 0.23––
First nine months 2026 diluted EPSGAAP$ 0.64––
First nine months 2026 adjusted operating EBITDAnon-GAAP$1.24B–1%
First nine months 2026 adjusted operating EBITDA marginnon-GAAP21.4%–0.4%
First nine months 2026 adjusted EPSnon-GAAP$ 1.84––
First nine months 2026 adjusted EPS ex. amortizationnon-GAAP$ 2.58––
First nine months 2026 net cash provided by operating activitiesGAAP820––
First nine months 2026 additions to property, plant and equipmentGAAP(449)––
First nine months 2026 free cash flownon-GAAP$371M–increasing $245 million year-over-year
September 30, 2026 net debt to credit adjusted EBITDAnon-GAAP2.75x––
September 30, 2026 total debt to trailing twelve months net incomeother34.5x––

Segments

SegmentRevenueq/qy/y
TasteComparable currency neutral sales increased 6% with broad-based growth in all regions led by a double-digit increase in Greater Asia. Comparable currency neutral adjusted operating EBITDA increased 7% driven by volume growth.$687M–4%
Health & BiosciencesComparable currency neutral sales increased 1% with growth in nearly all businesses. Mid-single digit growth in Food Biosciences and Grain Processing more than offset a decline in Health. Comparable currency neutral adjusted operating EBITDA increased 2%.$566M–1%
ScentComparable currency neutral sales increased 6% led by high-single digit growth in Consumer Fragrances. Fine Fragrance and Fragrance Ingredients both grew mid-single digits. Comparable currency neutral adjusted operating EBITDA increased 10% driven by volume growth.$689M–6%

Amounts quoted below without a unit are in millions, as in the filing’s tables. Per-share figures are as printed.

Full year 2026 outlook

  • Revenue$7.5 billion to $7.6 billion
  • NoteAdjusted operating EBITDA: $1.55 billion to $1.60 billion
  • NoteComparable currency neutral sales growth: 3% to 4%
  • NoteComparable currency neutral adjusted operating EBITDA growth: 5% to 8%
  • NoteForeign exchange is expected to have an approximately 1% positive impact on sales growth
  • NoteForeign exchange is expected to have an approximately 2% positive impact on adjusted operating EBITDA growth in 2026

Capital returns

  • Recently completed $500 million accelerated share repurchase program.
  • Purchases of treasury stock were $(584) million for the nine months ended September 30, 2026.
  • Cash dividends paid to shareholders were $(306) million for the nine months ended September 30, 2026.

What drove it

  • Reported Q3 net sales increased 4%, while comparable currency neutral sales increased 5%, led by broad-based growth.
  • Volume growth drove comparable currency neutral adjusted operating EBITDA improvement in Taste and Scent.
  • Health & Biosciences EBITDA improvement reflected an even contribution from volume growth and favorable net price to input costs.
  • The company said customers continue to value its strong R&D and innovation.
  • The Food Ingredients divestiture is progressing and is on track to close by the end of the second quarter of 2027.

Concerns

  • Q3 loss from continuing operations before taxes was $(134) million, including a $236 million loss on assets classified as held for sale.
  • Q3 operating profit declined (16) % and reported diluted EPS from continuing operations was $(0.50).
  • Management expects fourth-quarter profitability to be softer, particularly in Health & Biosciences, reflecting higher costs and reinvestments to strengthen the business.
  • Health & Biosciences comparable currency neutral sales increased 1%, and Health declined despite growth in Food Biosciences and Grain Processing.
  • Regulatory costs were $34 million in Q3 and $115 million for the first nine months of 2026.

What to watch

  • Fourth-quarter profitability, particularly in Health & Biosciences, where management expects higher costs and reinvestment.
  • Delivery against full-year sales guidance of $7.5 billion to $7.6 billion and adjusted operating EBITDA guidance of $1.55 billion to $1.60 billion.
  • Progress toward closing the Food Ingredients divestiture by the end of the second quarter of 2027.
  • The effect of approximately 1% positive foreign exchange impact on sales growth and approximately 2% positive foreign exchange impact on adjusted operating EBITDA growth.
  • Leverage following the accelerated share repurchase program, debt activity, and the planned Food Ingredients separation.

Balance sheet and cash flow

  • Cash and cash equivalents were $ 272 as of September 30, 2026, compared with $ 347 as of December 31, 2025.
  • Cash and cash equivalents, including amounts in discontinued operations and assets held for sale, were $ 519 as of September 30, 2026.
  • Short-term borrowings were $ 1,538 and long-term debt was $ 4,735 as of September 30, 2026.
  • Total debt was $ 6,307 and net debt was $ 5,788 as of September 30, 2026.
  • Net cash provided by operating activities was 820 for the nine months ended September 30, 2026, compared with 532 in 2025.
  • Net cash used in financing activities was (609) for the nine months ended September 30, 2026, compared with (2,891) in 2025.
  • Net proceeds received from business disposals were 247 for the nine months ended September 30, 2026, compared with 2,707 in 2025.

Analysis

IFF reported stronger third-quarter underlying operating performance on a continuing-operations basis. Net sales were $ 1,942, up 4 %, and comparable currency neutral sales increased 5%. The growth was broad-based across the portfolio, with Taste and Scent each delivering 6% comparable currency neutral sales growth and Health & Biosciences growing 1%. The company attributed the performance to solid volumes and customer demand for R&D and innovation.

Profit performance was stronger on an adjusted basis but was obscured in reported results by disposal-related charges. Adjusted operating EBITDA was $ 403, compared with $ 384, while adjusted operating EBITDA margin was 20.8%, compared with 20.5 %. Scent delivered the largest comparable currency neutral adjusted operating EBITDA increase at 10%, followed by Taste at 7%. Reported operating profit fell to 160 from 191, and the company recorded a $236 million loss on assets classified as held for sale, contributing to a $(134) million loss from continuing operations before taxes and $(0.50) diluted EPS from continuing operations.

Cash generation was a major feature of the release. Net cash provided by operating activities was 820 for the first nine months, compared with 532 in the prior-year period. The company reported free cash flow of $371 million, increasing $245 million year-over-year. Capital allocation included completion of a $500 million accelerated share repurchase program, purchases of treasury stock of $(584) million, and cash dividends paid to shareholders of $(306) million. Net debt was $ 5,788 at September 30, 2026, and net debt to credit adjusted EBITDA was 2.75x.

IFF raised the low end of all principal full-year operating outlook ranges. Sales guidance is now $7.5 billion to $7.6 billion, versus $7.4 billion to $7.6 billion previously, and adjusted operating EBITDA guidance is now $1.55 billion to $1.60 billion, versus $1.53 billion to $1.60 billion previously. Comparable currency neutral sales growth guidance moved to 3% to 4%, and comparable currency neutral adjusted operating EBITDA growth guidance moved to 5% to 8%. Management nevertheless expects fourth-quarter profitability to be softer, particularly in Health & Biosciences, due to higher costs and reinvestments.

Portfolio actions remain material to the reported financial profile. Results are presented on a continuing-operations basis, excluding the Food Ingredients disposal group, SCL disposal group, and other minor perimeter adjustments. The Food Ingredients divestiture is on track to close by the end of the second quarter of 2027. Investors should monitor disposal-related charges, regulatory costs, the expected Health & Biosciences margin pressure in the fourth quarter, and execution against the raised full-year outlook.

Management, verbatim

IFF delivered a solid third quarter, with improved sales and profitability across all divisions.

Erik Fyrwald, CEO of IFF

Heading into year-end, we are raising the low end of our full-year financial guidance ranges, supported by our year-to-date performance.

Erik Fyrwald, CEO of IFF

Not in the filing

stated, not guessed
  • Prior-quarter comparisons were not reported for the presented Q3 metrics.
  • Q3 operating cash flow and Q3 free cash flow were not reported.
  • A Q3 GAAP gross margin percentage was not reported.
  • Full-year 2026 guidance for gross margin, operating expenses, and tax rate was not reported.
  • A reported Q3 cash balance including discontinued operations was not presented as a Q3 comparative metric; the filing presents the combined cash and cash equivalents reconciliation as of September 30, 2026.
  • The previous outlook covered the full year 2026 only, so there is nothing to compare for this quarter.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Second Quarter 2026

AlphAI · Earnings readIFF · Second Quarter 2026 · ended June 30, 2026

IFF Reports Second Quarter 2026 Results; Announces Use of Proceeds Plan for Food Ingredients Divestiture

✓Strong quarter

Continuing-operations sales increased 2% on a reported basis and 6% on a comparable currency neutral basis, while adjusted operating EBITDA reached $408 million and free cash flow increased $284 million year-over-year for the first six months. All three continuing segments posted comparable currency neutral sales and adjusted operating EBITDA growth, alongside a $2.5 billion enhanced share repurchase authorization.

Revenue
$1.95B
2% y/y
Taste
$688M
5% reported sales growth; 4% comparable currency neutral sales growth; 6% adjusted operating EBITDA growth; 6% comparable currency neutral adjusted operating EBITDA growth y/y
EPS · non-GAAP
$0.82
Full year 2026, continuing operations outlook
$7.4 billion to $7.6 billion

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, second quarter, continuing operationsGAAP$1.95B–2%
Comparable currency neutral sales, second quarter, continuing operationsnon-GAAP: increased 6%–6%
Net sales, second quarter, inclusive of discontinued operationsGAAP$2.78B––
Income from continuing operations before taxes, second quarterGAAP$64M––
Adjusted operating EBITDA, second quarter, continuing operationsnon-GAAP$408M––
Comparable currency neutral adjusted operating EBITDA, second quarter, continuing operationsnon-GAAP: improved 6%–6%
Adjusted operating EBITDA margin, second quarter, continuing operationsnon-GAAP20.9%––
Adjusted operating EBITDA, second quarter, discontinued operationsnon-GAAP$140M––
Adjusted operating EBITDA, second quarter, inclusive of discontinued operationsnon-GAAP$548M––
Reported EPS, second quarterGAAP$0.13 per diluted share––
Adjusted EPS excluding amortization, second quarternon-GAAP$0.82 per diluted share––
Sales, first six months, continuing operationsGAAP$3.9B––
Income before taxes, first six months, continuing operationsGAAP$260M––
EPS, first six months, continuing operationsGAAP$0.73––
Adjusted operating EBITDA, first six months, continuing operationsnon-GAAP$841M––
Adjusted operating EBITDA margin, first six months, continuing operationsnon-GAAP21.8%––
EPS excluding amortization, first six months, continuing operationsnon-GAAP$1.74––
Cash flows from operations, first six months, continuing and discontinued operationsother$679M–increasing $311 million year-over-year
Free cash flow, first six months, continuing and discontinued operationsnon-GAAP$378M–increasing $284 million year-over-year
Total debt to trailing twelve months net income, end of second quarterother22.6x––
Net debt to credit adjusted EBITDA, end of second quarternon-GAAP2.5x––
Adjusted operating EBITDA margin, second quarter, including discontinued operationsnon-GAAP19.7%––

Segments

SegmentRevenueq/qy/y
TasteBroad-based growth in all regions. Comparable currency neutral adjusted operating EBITDA increased primarily due to volume growth and favorable net pricing.$688M–5% reported sales growth; 4% comparable currency neutral sales growth; 6% adjusted operating EBITDA growth; 6% comparable currency neutral adjusted operating EBITDA growth
Health & BiosciencesGrowth in all businesses, led by Grain Processing, Food Biosciences & Animal Nutrition. Comparable currency neutral adjusted operating EBITDA increased primarily due to volume growth.$601M–8% reported sales growth; 5% comparable currency neutral sales growth; 8% adjusted operating EBITDA growth; 6% comparable currency neutral adjusted operating EBITDA growth
ScentDouble-digit growth in Fragrance Ingredients and a high single-digit performance in Consumer Fragrance. Fine Fragrance increased low-single digits compared to the prior year period as it was impacted by the Middle East conflict.$665M–10% reported sales growth; 8% comparable currency neutral sales growth; 11% adjusted operating EBITDA growth; 5% comparable currency neutral adjusted operating EBITDA growth

Full year 2026, continuing operations outlook

  • Revenue$7.4 billion to $7.6 billion
  • NoteAdjusted operating EBITDA: $1.53 billion to $1.60 billion
  • Noteexcluding approximately $3.2 billion related to discontinued operations

Capital returns

  • Enhanced share repurchase authorization with a total value of $2.5 billion, including approximately $400 million remaining on its prior authorization.
  • Accelerated share repurchase of $500 million expected to be executed in the second half of 2026.
  • Remaining $2.0 billion share repurchase expected to be executed following the closing of the Food Ingredients disposal group divestiture, with expected completion by the end of 2027.
  • The Company plans to fund repurchases from cash provided by operating activities, short-term debt and net cash proceeds provided by the divestiture of the Food Ingredients disposal group.

What drove it

  • Reported net sales increased 2% versus the prior-year period, while comparable currency neutral sales increased 6%, led by broad-based growth including high-single digit performance in Scent and mid-single digit growth in Taste and Health & Biosciences.
  • Comparable currency neutral adjusted operating EBITDA improved 6%, driven primarily by volume growth and productivity gains.
  • The Food Ingredients disposal group and the SCL disposal group are reported as discontinued operations, leaving Taste, Scent and Health & Biosciences as continuing operations.
  • IFF expects to eliminate approximately two thirds of stranded costs within the first year following transaction close and substantially all within two years following transaction close.

Concerns

  • Fine Fragrance was impacted by the Middle East conflict.
  • Stranded costs related to the Food Ingredients transaction represent approximately $100 million of corporate and functional expenses previously allocated to the Food Ingredients business that are expected to remain with IFF following the close.
  • The Food Ingredients disposal group sale is subject to customary closing conditions and receipt of regulatory approvals, and is expected to close by the end of the second quarter of 2027.
  • Net debt to credit adjusted EBITDA was 2.5x at the end of the second quarter and includes the effects of both continuing and discontinued operations.

What to watch

  • Execution of the $500 million accelerated share repurchase in the second half of 2026.
  • Progress toward the expected close of the Food Ingredients disposal group sale by the end of the second quarter of 2027.
  • Execution of the remediation plan for approximately $100 million of stranded costs.
  • Delivery against full-year continuing-operations sales guidance of $7.4 billion to $7.6 billion and adjusted operating EBITDA guidance of $1.53 billion to $1.60 billion.

Balance sheet and cash flow

  • Cash flows from operations for the first six months of the year for continuing and discontinued operations was $679 million, increasing $311 million year-over-year.
  • Free cash flow, defined as cash flows from operations less capital expenditures, totaled $378 million, increasing $284 million year-over-year.
  • Total debt to trailing twelve months net income at the end of the second quarter was 22.6x.
  • Net debt to credit adjusted EBITDA at the end of the second quarter was 2.5x, and includes the effects of both continuing and discontinued operations.
  • Food Ingredients disposal group sale has net cash proceeds of approximately $3.8 billion, subject to customary transaction adjustments.

Analysis

IFF reported a strong second quarter on a continuing-operations basis. Reported net sales were $1.95 billion, up 2% versus the prior-year period, while comparable currency neutral sales increased 6%. Management attributed growth to broad-based demand, including high-single digit performance in Scent and mid-single digit growth in Taste and Health & Biosciences. Each continuing segment delivered comparable currency neutral sales growth, led by Scent at 8%.

Profitability advanced with adjusted operating EBITDA of $408 million and a 20.9% adjusted operating EBITDA margin. Comparable currency neutral adjusted operating EBITDA improved 6%, driven primarily by volume growth and productivity gains. Segment profitability was supported by volume growth and favorable net pricing in Taste, volume growth in Health & Biosciences, and volume growth and productivity in Scent. Continuing-operations adjusted operating EBITDA margin was higher than the 19.7% margin including discontinued operations.

Cash generation was a major feature of the first half. Cash flows from operations for continuing and discontinued operations were $679 million, increasing $311 million year-over-year, and free cash flow totaled $378 million, increasing $284 million year-over-year. At quarter-end, total debt to trailing twelve months net income was 22.6x, while net debt to credit adjusted EBITDA was 2.5x. The latter ratio includes the effects of both continuing and discontinued operations.

Portfolio transformation is central to the reported outlook and capital-allocation framework. The planned Food Ingredients disposal group sale carries net cash proceeds of approximately $3.8 billion, subject to customary transaction adjustments, and is expected to close by the end of the second quarter of 2027. IFF plans to apply net proceeds to reduce outstanding debt by over $1 billion, while its Board authorized a $2.5 billion repurchase program that includes a $500 million accelerated share repurchase expected in the second half of 2026. The transaction also leaves approximately $100 million of stranded costs, with remediation actions intended to eliminate approximately two thirds within the first year after close and substantially all within two years.

IFF introduced full-year 2026 continuing-operations guidance for sales of $7.4 billion to $7.6 billion and adjusted operating EBITDA of $1.53 billion to $1.60 billion. The new basis excludes approximately $3.2 billion related to discontinued operations. The key operational items are delivery of broad-based volume growth and productivity, the impact of the Middle East conflict on Fine Fragrance, execution against stranded-cost remediation, and completion of the Food Ingredients divestiture and associated capital-return plan.

Management, verbatim

IFF delivered a strong first half of 2026 on a continuing operations basis. Performance was driven by volume growth, disciplined margin execution and robust free cash flow generation. These results reflect the strength of our commercial and innovation pipelines and the actions underway to improve efficiency and cash flow across the company.

Erik Fyrwald, CEO of IFF

This quarter marked a defining step in our portfolio transformation with the announced agreement to divest Food Ingredients. The transaction sharpens IFF's focus on Taste, Scent, and Health & Biosciences, creating a simpler, higher-growth, higher-margin company with enhanced cash generation. As part of this transformation, we are taking decisive action to eliminate related stranded costs and will execute with urgency.

Erik Fyrwald, CEO of IFF

With Food Ingredients now reported as discontinued operations, we are introducing full-year 2026 guidance on a continuing operations basis. The underlying performance in the three business units is consistent with previous guidance given. The new presentation provides greater visibility into the growth and margin profile of our go-forward portfolio, reinforcing the outlook for IFF’s continuing operations and our ability to create long-term shareholder value.

Erik Fyrwald, CEO of IFF

Not in the filing

stated, not guessed
  • Full financial guidance text following the reported adjusted operating EBITDA range was truncated in the provided filing text.
  • GAAP net income for the second quarter and first six months was not provided in the supplied text.
  • Gross margin, operating income, operating margin, tax rate, cash balance, total debt balance, and capital expenditures were not provided in the supplied text.
  • Prior-year absolute values for most reported metrics were not provided in the supplied text.
  • Prior-quarter comparisons were not provided in the supplied text.
  • Segment prior-year revenue amounts and prior-quarter segment comparisons were not provided in the supplied text.
  • A dividend amount or dividend declaration was not provided in the supplied text.
  • Guidance on gross margin, operating expenses, tax rate, EPS, free cash flow, capital expenditures, and cash flow was not provided in the supplied text.
  • Previous-release outlook was not provided, so reported results cannot be compared with prior guidance.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Questions about IFF earnings dates

When is International Flavors & Fragrances's next earnings date?
AlphAI has no date for IFF yet. We do not publish estimates, so this page shows a date the day we have one.
Why is there sometimes no date?
AlphAI leaves out estimates. Many sites fill the gap by adding about 91 days to the last report, but that arithmetic is a guess, and a wrong date costs a reader more than a missing one, so we show nothing until a date is set, and a company can still move it. Every quarter already on this page is read straight from the SEC filing: an 8-K item 2.02 for US filers, a 6-K earnings release for foreign private issuers.